Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene

Godlewska, Beata R.; Olajossy-Hilkesberger, Luiza; Ciwoniuk, M; Olajossy, Marcin; Marmurowska-Michałowska, Halina; Limon, Janusz; Landowski, Jerzy

doi:10.1038/tpj.2009.18

Cited by 57 publications

(49 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…6 For later SWG, additional risk factors have been proposed: older age, high BMI, female sex, 4 parents' BMI, 4 nonsmoker, 4 fluoxetine dose, country of residence, 12 housing conditions, 12 preoccupation with food thoughts, 12 treatment efficacy, 14 exercise levels, and genetic variants. 10,11,32 Owing to the different patient populations and study designs, direct comparisons of results between the present and other studies cannot be made; however, although our analysis and results do differ methodologically from some of those previously reported for OLZ treatment, they remain consistent. For example, in a study of patients with bipolar disorder who took OLZ, EWG predicted SWG (defined as Q5 kg at 30 weeks) 25 when 2 to 3 kg defined EWG in a time frame of 3 weeks.…”

Section: Discussionsupporting

confidence: 43%

Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination

Degenhardt

Jamal²,

Tormey³

et al. 2011

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Weight gain during olanzapine/fluoxetine combination (OFC) therapy is very common. We examined early (at 2 weeks) weight gain as a predictor of later (at 26 weeks) substantial weight gain in patients with treatment-resistant depression during OFC pharmacotherapy. Data were analyzed from 2 studies (Study 1 and Study 2)-each with an acute, double-blind phase and an open-label phase-in patients who completed 26 weeks of open-label treatment (N = 306). Mean patient age was 46 years; the majority was female and white. Sensitivity, specificity, and positive and negative predictive values (PPV and NPV) were examined using early weight gain of 2 kg or more as a predictor of 10 kg or more substantial weight gain. Sensitivity (true positive rate) and specificity for Study 1 (n = 73) were 33% and 71%, respectively; PPV and NPV were 23% and 80%, respectively. Sensitivity and specificity for Study 2 (n = 233) were 52% and 70%, respectively; PPV and NPV were 31% and 85%, respectively. Overall, in the 2 trials analyzed, for patients who did not gain 2 kg or more (2.54 lb) in the first 2 weeks of OFC treatment, the observed frequency was 16.3% for gaining 10 kg or more at 26 weeks. Compared to those with early weight gain, patients without early weight gain were less likely to have substantial weight gain after OFC treatment. Additional research is needed to further explore the predictive power of early weight gain for subsequent substantial weight gain in patients with treatment-resistant depression treated with OFC.

show abstract

Section: Discussionsupporting

confidence: 43%

Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination

Degenhardt

Jamal²,

Tormey³

et al. 2011

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…This was unexpected as the 759 C/T polymorphism has been repeatedly associated with antipsychotic-induced weight gain, and weight gain is an important predictor for meeting the criteria for the metabolic syndrome. 12,[16][17][18][19][20][21][22][23][24] The fact that this is the third study in which we found an association between prevalence of the metabolic syndrome and HTR2C rs1414334 genotype, but not 759C/T genotype, requires an explanation. We suggest that we are dealing with two different phenotypes in two different phases of the disease with weight gain at the initiation of treatment and the presence (and prevalence) of the metabolic syndrome, after a longer period of treatment with antipsychotic drugs.…”

mentioning

confidence: 68%

“…It has been shown that the 759 C/T polymorphism affects the HTR2c transcription rate, with the 759 T-allele leading to a higher expression of the 5HT 2C -receptor. 12 Therefore, patients carrying the 759 T-allele will likely be protected against weight gain caused by HTR2c inhibition by antipsychotics. The intronic position of the rs1414334 polymorphism suggests that this polymorphism is nonfunctional.…”

Section: Determinantsmentioning

confidence: 99%

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study

et al. 2010

View full text Add to dashboard Cite

In two previous studies we found an association between HTR2C polymorphisms and the prevalence of the metabolic syndrome in patients using antipsychotics. In this study, we set out to replicate our findings in a third separate sample of patients. Data for this cross-sectional study came from the ongoing Pharmacotherapy Monitoring and Outcome survey study, investigating the association between schizophrenia and metabolic or cardiovascular risk factors. Primary end point was the prevalence of the metabolic syndrome. Primary determinants were two polymorphisms in the HTR2C gene: rs3813929 (À759 C/T) and rs1414334:C4G. Carriership of the variant rs1414334 C-allele was significantly associated with an increase prevalence of the metabolic syndrome (odds ratio (OR) 3.73; 95% confidence interval (CI) 1.29-10.79, P ¼ 0.015). No association was found between the HTR2C À759 C/T polymorphism and the metabolic syndrome. This study confirms previous findings that the variant C-allele of the rs1414334 polymorphism is associated with the metabolic syndrome.

show abstract

“…Buckland et al [27] described that this genetic variant influences gene expression: the C allele confers lower activity to 5-HTR2C. The rs3813929 polymorphism has been extensively evaluated regarding its impact on the anthropometric patterns on individuals taking antipsychotics, and the T allele was repeatedly associated with a protective effect on antipsychotic-induced bodyweight gain (BWG) [28,29]. However, not all subsequent independent studies have reported these findings [30][31][32], and one study even reported a larger BWG in carriers of the T allele, with hemizygous T allele men gaining significantly more weight than hemizygous C allele men after 4 months of treatment with clozapine, a potent 5-HTR2C antagonist [33].…”

Section: Discussionmentioning

confidence: 99%

SLC6A14 and 5-HTR2C polymorphisms are associated with food intake and nutritional status in children

Miranda

Vetter

Genro

et al. 2015

Clinical Biochemistry

View full text Add to dashboard Cite

Olanzapine-induced weight gain is associated with the −759C/T and −697G/C polymorphisms of the HTR2C gene

Cited by 57 publications

References 31 publications

Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination

Early Weight Gain as a Predictor of Substantial Weight Gain With Olanzapine/Fluoxetine Combination

Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study

SLC6A14 and 5-HTR2C polymorphisms are associated with food intake and nutritional status in children

Contact Info

Product

Resources

About